Literature DB >> 25918300

Use of Imaging for GI Cancers.

Stuart Bentley-Hibbert1, Lawrence Schwartz2.   

Abstract

GI cancers are a heterogeneous group of neoplasms that differ in their biologic and physical behaviors depending on the organ of origin, location within the organ, and degree of differentiation. As a result, evaluation of these tumors is complex, requiring integration of information from a patient's clinical history, physical examination, laboratory data, and imaging. With advances in anatomic and functional imaging techniques, we now have tools for assessing patients with these tumors at diagnosis, staging, and treatment assessment. It is difficult for a single imaging modality to provide all the necessary information for a given GI tumor. However, well-chosen combinations of available imaging modalities based on the indications, strength, and limitations of the modalities will provide optimal evaluation of patients with these malignancies.
© 2015 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2015        PMID: 25918300     DOI: 10.1200/JCO.2014.60.2847

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  3 in total

1.  Special Series: Advances in GI Cancer.

Authors:  Jeffrey A Meyerhardt; Joel E Tepper; Alan P Venook
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 2.  Beyond gastric adenocarcinoma: Multimodality assessment of common and uncommon gastric neoplasms.

Authors:  Danielle M Richman; Sree Harsha Tirumani; Jason L Hornick; Charles S Fuchs; Stephanie Howard; Katherine Krajewski; Nikhil Ramaiya; Michael Rosenthal
Journal:  Abdom Radiol (NY)       Date:  2017-01

3.  Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management.

Authors:  Chunxia Qin; Yangmeihui Song; Yongkang Gai; Weiwei Ruan; Qingyao Liu; Fang Liu; Danzha Zheng; Peng Zhang; Hongli Liu; Tao Zhang; Kaixiong Tao; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-03       Impact factor: 10.057

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.